Clinical Progress of Glutaminase Inhibitors Glutaminase inhibitors selectively target the overactive GLS in cancer cells, sparing GLS2 in normal cells: Blocking EMT (Epithelial-to-Mesenchymal Transition) : These inhibitors can help prevent EMT, which supports cancer spread
Food and Drug Administration) There are case reports and small studies showing deranged liver function tests and possible renal stress after IV glutathione
using it in people, or selling it while implying a therapeutic or muscle-building benefit, can trigger FDA enforcement action against the seller
Ling H, Spizzo R, Atlasi Y, Nicoloso M, Shimizu M, Redis RS, Nishida N, Gaf R, Song J, Guo Z, Ivan C, Barbarotto E, De Vries I, Zhang X, Ferracin M, Churchman M, van Galen JF, Beverloo BH, Shariati M, Haderk F, Estecio MR, Garcia-Manero G, Patijn GA, Gotley DC, Bhardwaj V, Shureiqi I, Sen S, Multani AS, Welsh J, Yamamoto K, Taniguchi I, Song MA, Gallinger S, Casey G, Thibodeau SN, Le Marchand L, Tiirikainen M, Mani SA, Zhang W, Davuluri RV, Mimori K, Mori M, Sieuwerts AM, Martens JW, Tomlinson I, Negrini M, Berindan-Neagoe I, Foekens JA, Hamilton SR, Lanza G, Kopetz S , Fodde R , Calin GA
doi: 10.1038/s41586019-17052 107 ChuJLiuCXSongRLiQL